Novel Biomarkers for Limb Girdle Muscular Dystrophy (LGMD)

Sara Aguti,Gian Nicola Gallus,Silvia Bianchi,Simona Salvatore,Anna Rubegni,Gianna Berti,Patrizia Formichi,Nicola De Stefano,Alessandro Malandrini,Diego Lopergolo,Nicola De De Stefano

DOI: https://doi.org/10.3390/cells13040329

IF: 6

2024-02-11

Cells

Abstract:Objective: To identify novel biomarkers as an alternative diagnostic tool for limb girdle muscular dystrophy (LGMD). Background: LGMD encompasses a group of muscular dystrophies characterized by proximal muscles weakness, elevated CK levels and dystrophic findings on muscle biopsy. Heterozygous CAPN3 mutations are associated with autosomal dominant LGMD-4, while biallelic mutations can cause autosomal recessive LGMD-1. Diagnosis is currently often based on invasive methods requiring muscle biopsy or blood tests. In most cases Western blotting (WB) analysis from muscle biopsy is essential for a diagnosis, as muscle samples are currently the only known tissues to express the full-length CAPN3 isoform. Methods: We analyzed CAPN3 in a cohort including 60 LGMD patients. Selected patients underwent a complete neurological examination, electromyography, muscle biopsy, and skin biopsies for primary fibroblasts isolation. The amount of CAPN3 was evaluated by WB analysis in muscle and skin tissues. The total RNA isolated from muscle, fibroblast and urine was processed, and cDNA was used for qualitative analysis. The expression of CAPN3 was investigated by qRT-PCR. The CAPN3 3D structure has been visualized and analyzed using PyMOL. Results: Among our patients, seven different CAPN3 mutations were detected, of which two were novel. After sequencing CAPN3 transcripts from fibroblast and urine, we detected different CAPN3 isoforms surprisingly including the full-length transcript. We found comparable protein levels from fibroblasts and muscle tissue; in particular, patients harboring a novel CAPN3 mutation showed a 30% reduction in protein compared to controls from both tissues. Conclusions: Our findings showed for the first time the presence of the CAPN3 full-length transcript in urine and skin samples. Moreover, we demonstrated surprisingly comparable CAPN3 protein levels between muscle and skin samples, thus allowing us to hypothesize the use of skin biopsy and probably of urine samples as an alternative less invasive method to assess the amount of CAPN3 when molecular diagnosis turns out to be inconclusive.

cell biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to identify new biomarkers for Limb Girdle Muscular Dystrophy (LGMD) as an alternative diagnostic tool. Currently, the diagnosis of LGMD usually depends on invasive methods, such as muscle biopsy or blood tests. Muscle biopsy is essential in most cases because only muscle tissue can express the full - length CAPN3 isoform. However, these methods are more painful for patients and carry certain risks. Therefore, researchers hope to reduce the dependence on invasive methods by discovering new biomarkers, especially those that can be detected in non - muscle tissues, so as to provide a simpler and less invasive diagnostic method.

Specifically, the researchers analyzed the expression of the CAPN3 gene in a group of LGMD patients. By detecting the CAPN3 protein levels and mRNA expression in different tissues (such as muscle, skin and urine), they aimed to explore whether skin biopsy or urine samples could be used as alternative methods to evaluate CAPN3 levels, especially in cases where the molecular diagnosis results were uncertain. The research results showed that full - length CAPN3 transcripts do exist in skin and urine samples, and in some cases, the CAPN3 protein levels in skin and muscle tissues are comparable, which provides the possibility for the future development of a simpler LGMD diagnostic method.